Norepinephrine

References discuss Fuchs Endothelial Corneal Dystrophy, oxidative stress, DNA damage, and ATM activation in various contexts, including clinical, genetic, and therapeutic aspects.

Evidence-based guidelines on repetitive transcranial magnetic stimulation (rTMS) for therapeutic use, neurobiological predictors of response, and neurostimulation interventions for treatment-resistant depression are discussed, focusing on the role of the locus coeruleus and its impact on brain function and depression.

A randomized controlled crossover trial found that cold fluid bolus therapy significantly increased MAP, systemic vascular resistance, and intrinsic noradrenaline levels, without activating adrenaline or the renin–angiotensin–aldosterone system. This prolonged effect on MAP was not observed with fluids at body temperature. The study suggests that fluid temperature, rather than volume alone, contributes to MAP increase in fluid bolus therapy, challenging current physiological principles and potentially offering a cost-effective treatment option for hypotensive patients.

Scientists at McGill University discovered the melatonin MT1 receptor's role in regulating REM sleep, offering potential for new treatments for sleep disorders and neuropsychiatric conditions. A novel drug targeting MT1 extended REM sleep in animal studies, highlighting its clinical potential. The study, published in the Journal of Neuroscience, suggests a paradigm shift in sleep disorder treatment.